The rationale for including immune checkpoint inhibition into multimodal primary treatment concepts of head and neck cancer.

ABSTRACT:

Background

Treatment of locally advanced squamous cell carcinomas of the head and neck (SCCHN) remains unsatisfactory. Although the addition of concurrent radiochemotherapy (RCT) or the combination of radiotherapy with blockade of the epidermal growth factor receptor (EGFR) have improved outcomes over radiotherapy alone, further optimization is urgently needed. The introduction of immune checkpoint inhibitors is currently revolutionizing cancer treatment. Clinical evidence has recently been provided in melanoma that immune checkpoint blockade may cooperate with radiation. Therefore, we searched in the literature for the evidence of combining immune checkpoint inhibitors with radiotherapy in primary treatment of SCCHN.

Discussion

A substantial amount of previous studies has d

SUBMITTER: Tinhofer I 

PROVIDER: S-EPMC6460729 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature